Replimune Group Inc. (REPL)
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
REPL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.81B
- EPS (TTM)
- -$2.79
- Dividend yield
- None
- 52-week range
- 1.50 – 23.54
- Day range
- 18.70 – 19.50
- Volume / Avg
- 1.96M / 2.48M
- Beta
- —
- Shares outstanding
- 94.80M
52-week range
REPL stock today
Shares of Replimune Group (REPL) finished lower on Nov 20 at $19.07, a drop of 0.83% or $0.16 per share, versus the S&P 500's 3.70% decline. Shares are 19.0% below their 52-week high of $23.54, set on Nov 10, 2026 and 1171.3% above the 52-week low of $1.50, in the middle of the past year's range. REPL is up 96.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 107.3%.
Replimune Group has posted a net loss over the last twelve months (EPS of -$2.79), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Replimune Group
Company profileReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Sushil Patel Ph.D.
- Headquarters
- Woburn, MA
- Employees
- 465
- IPO year
- 2018
- Website
- replimune.com
Financial highlights
Full financialsReplimune Group reported a net loss of $313.9 million, compared with a loss of $247.3 million a year earlier. Diluted earnings per share came in at -$3.38.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-313.94M | $-247.30M | $-215.79M | $-174.28M | $-118.04M |
| EPS (diluted) | $-3.38 | $-3.07 | $-3.24 | $-2.99 | $-2.26 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$25.50+33.72%
- Strong buy 2
- Buy 5
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $-0.54 vs $-0.70
- Surprise
- +22.86%
REPL news
All REPL news- REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline ProgressNasdaqREPL, BMY, ADPT, ACIU
- Replimune Group Consensus Price Target Increased by 14.78% to $22.44NasdaqREPL, LEN.B
- Replimune: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Replimune (REPL) Q2 2027 Earnings Call TranscriptNasdaq
- Replimune anticipates permanent J-code by April 2027 as TUDRIQEV launch metrics buildSeeking Alpha
- Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%NasdaqAXGN, GMAB, KIDS, LUNG
- Replimune Group, Inc. Reports Fiscal Second Quarter 2027 Financial Results and TUDRIQEV LaunchNasdaq
- Replimune Posts Narrower Loss In Q2NasdaqREPL, HEI.A
Replimune Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| COAGHemab Therapeutics Holdings Inc. | 39.29 | -1.43% | $1.84B | vs REPL |
| BCRXBioCryst Pharmaceuticals Inc. | 7.22 | -1.37% | $1.86B | vs REPL |
| LYCALycia Therapeutics Inc. | 33.07 | +4.09% | $1.72B | vs REPL |
| MAZEMaze Therapeutics Inc. | 31.37 | -3.27% | $1.72B | vs REPL |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs REPL |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs REPL |
| BEAMBeam Therapeutics Inc. | 20.90 | -0.19% | $2.16B | vs REPL |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs REPL |
Indexes, lists and sector
Replimune Group stock FAQ
What is Replimune Group's stock price today?
REPL last traded at $19.07 as of Nov 20, 4:00 PM EST, down 0.83% on the day. Prices are delayed at least 15 minutes.
Who is Replimune Group's CEO?
Dr. Sushil Patel Ph.D. is the chief executive officer of Replimune Group Inc., which has about 465 employees.
What is the REPL 52-week high?
The 52-week high for REPL is $23.54 and the 52-week low is $1.50. The stock is currently 19.0% below its high.